The presented article describes data from secondary analyses, related to the research article entitled "Cannabis consumption and Non-Alcoholic Fatty Liver Disease. A three years longitudinal study in first episode non-affective psychosis patients" [1] . We present detailed data regarding the socio-demographic and baseline clinical characteristics of a sample of 390 drug-naïve patients with a first episode of non-affective psychosis, and the differences between cannabis users and non-users in those characteristics. Tables also show the results from cross-sectional and longitudinal statistical analyses exploring the relation between cannabis DOI of original article: https://doi.
Data
We present in this article data derived from secondary analyses of a previous study on the relation between cannabis consumption and NAFLD in a Spanish cohort of drug-naïve patients with a first episode of non-affective psychosis [1] . Raw data has been made accessible through the public data repository "Mendeley Data" at https://doi.org/10.17632/hwn48wt7j6.1. Table 1 describes some of the main clinical and socio-demographic characteristics of the global study sample and of each cannabis groups (consumers and no consumers). Table 2 describes the baseline and 3-years liver function tests differences between groups (cannabis users vs non users), after having excluded those patients with a moderate-severe alcohol consumption. Table 3 shows the longitudinal differences in liver function tests between groups (cannabis users, discontinuers, non-users), after having excluded those patients with a moderate-severe alcohol consumption.
Specifications Table

Subject area
Psychiatry; Hepatology More specific subject area First episode psychosis; NAFLD Type of data
Tables, text file How data was acquired Prospective cohort study, including clinical evaluation.
Data format
Raw and Analyzed
Experimental factors
Effect of cannabis consumption on the incidence of liver steatosis (NAFLD).
Experimental features
Patients diagnosed with a first episode of non-affective psychosis, and being drug-naïves, were included in a prospective cohort (PAFIP). Patients were treated with antipsychotic medication. Clinical, cognitive and physical examinations were carried out prospectively during the 3-years follow-up period.
Data source location
Autonomous region of Cantabria, Spain.
Data accessibility
Data available at the following public data repository: 
Value of the Data
Cannabis consumption is associated with key clinical and sociodemographic characteristics of the psychosis, such as age of onset, DUP or symptoms severity. After ruling out a probable confounding effect of alcohol drinking, cannabis was associated with a smaller risk of NAFLD in the first 3 years after psychosis breakout. Cannabis effect on liver tissue might be through the modulation of weight gain.
And Table 4 , presents the clinical impact of cannabis use over the 3 years period, again after having excluded those patients with a moderate-severe alcohol consumption.
Experimental design, materials and methods
Population description
To obtain the present data, we included adult patients presenting a first episode of non-affective psychosis between 2001 and 2015 (full description of inclusion criteria in Pelayo et al., 2008), for whom we had information of cannabis use (yes/no) both at baseline and at 3-years follow-up [2] . Patients were evaluated at baseline and periodically thereafter until year 3. Anthropometric measures and fasting blood samples for lipid, glycemic and liver determinations, were collected. Main NAFLD and liver fibrosis scores (FLI, FIB-4 and NAFLD fibrosis scores) were calculated accordingly to previous literature [3e5] . Cannabis and other drugs were recorded from patients self-reports. Table 1 shows the main clinical and socio-demographic characteristics of the study sample, and of each consuming groups (cannabis users and no users), at study entry. It also contains the results from the statistical analyses comparing these two groups regarding their clinical and sociodemographic characteristics. Patients reporting cannabis consumption were significantly younger than the nonconsumers. They also presented a shorter duration of untreated psychosis, and more severe psychotic symptomatology at study entry. More patients among the cannabis group reported smoking tobacco and drinking alcohol than in the no-cannabis group. Abbreviations: FLI, fatty liver Index; BMI, body mass index; GGT, Gamma-glutamyltransferase; AST, aspartate aminotransferase; ALT, alanine aminotransferase; AP, alkaline phosphatase; hsCRP, high sensitivity C-reactive protein; FIB-4, fibrosis 4 score; NAFLD, non-alcoholic fatty liver disease fibrosis score. a ANCOVA model: parameter was used as the dependent variable, cannabis use was the fixed factor and age, sex, and tobacco and alcohol consumption use were used as covariates. Abbreviations: FLI, fatty liver Index; BMI, body mass index; GGT, Gamma-glutamyltransferase; AST, aspartate aminotransferase; ALT, alanine aminotransferase; AP, alkaline phosphatase; hsCRP, high sensitivity C-reactive protein; FIB-4, fibrosis 4 score; NAFLD, non-alcoholic fatty liver disease fibrosis score. a ANCOVA model: mean differences after 3 years of treatment were used as dependent variables, evolution of cannabis use was the fixed factor and age, sex, and tobacco and alcohol use trajectories use were applied as covariates. 
Secondary analyses excluding patients with moderate-severe alcohol consumption
Due to the well-known deleterious effect of alcohol on liver, and despite being one of the study's exclusion criteria presenting an alcohol dependence, we considered appropriate carrying secondary analyses after exclusion of those patients with alcohol consumption qualifying for moderate-severe drinking. For this, moderate-severe alcohol use was defined using the accepted alcohol consumption thresholds for the diagnosis of NAFLD: 140 and 210 g of alcohol per week in women and men, respectively [6] . Tables 2e4 contains the results from the statistical analyses, both cross-sectional and longitudinal, after excluding these patients (n ¼ 40).
